Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Study of Pegvisomant in Acromegaly
NCT00143416Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegvisomant in acromegaly, sponsored by Pfizer. Primary endpoint: Safety and Efficacy of Long-Term Pegvisomant Therapy. Started Apr 2004; status: completed.
02
Drugs
pegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00143416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143416.